Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administrationof a vinyl sulfone cysteine protease inhibitor

Citation
Sl. Biroc et al., Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administrationof a vinyl sulfone cysteine protease inhibitor, ARTH RHEUM, 44(3), 2001, pp. 703-711
Citations number
28
Categorie Soggetti
Rheumatology,"da verificare
Journal title
ARTHRITIS AND RHEUMATISM
ISSN journal
00043591 → ACNP
Volume
44
Issue
3
Year of publication
2001
Pages
703 - 711
Database
ISI
SICI code
0004-3591(200103)44:3<703:CPAIUI>2.0.ZU;2-T
Abstract
Objective. Cysteine proteases are postulated to play a role in tissue destr uction in the joints of animals with arthritis. The purpose of the present study was to confirm the concept that cysteine proteases are enzymes involv ed in the pathology of rheumatoid arthritis (RA). Methods. Arthritis was induced in Lewis rats by adjuvant injection (adjuvan t-induced arthritis [AIA] model) and scored for inflammation. At necropsy, the rear paws were either fixed in formalin and assigned a histologic score (based on synovial cell proliferation, cartilage erosion, bone erosion, an d fibroproliferative pannus) or frozen, cryosectioned, and assayed for enzy me activity either by in situ cytochemical staining with a post-azo-couplin g method using a chromogenic substrate (Z-arg-arg-MNA) or by a novel assay placing the tissue section directly in a cuvette using the fluorogenic subs trate Z-arg-arg-AMC. Results. Enzymatic activity, measured either in frozen sections in situ or in the cuvette assay, was positively correlated with joint destruction (r = 0.7) and inflammation (r = 0.8). Activity was not inhibited significantly by Pefabloc (a serine protease inhibitor), EDTA (a metalloprotease inhibito r), or pepstatin A (an aspartyl protease inhibitor) but was inhibited by E- 64 and vinyl sulfone irreversible inhibitors of cysteine proteases. The eff ect of one of the vinyl sulfone cysteine protease inhibitors, Mu-Leu-HomoPh e-vinylsulfone, was tested in vivo by dietary administration at 2.2 mg/kg/d ay in the AIA model; this resulted in a significant decrease in inflammatio n and in the amount of cysteine protease activity measured in the joint tis sue. Conclusion. Cysteine protease activity levels increase in the diseased stat e and may be an important target for designing small molecule inhibitors to reduce the inflammation and tissue destruction associated with RA.